FLT3 | 13q12.2 | FLK2, STK1, CD135, FLK-2 | | -FLT3 and Acute Myeloid Leukaemia
| 1190 |
PML | 15q24.1 | MYL, RNF71, PP8675, TRIM19 | | -PML and Acute Myeloid Leukaemia
| 940 |
CD34 | 1q32.2 | | | -CD34 and Acute Myeloid Leukaemia
| 645 |
NPM1 | 5q35.1 | B23, NPM | | -NPM1 and Acute Myeloid Leukaemia
| 605 |
BCR | 22q11.23 | ALL, CML, PHL, BCR1, D22S11, D22S662 | | -BCR and Acute Myeloid Leukaemia
| 580 |
KITLG | 12q22 | SF, MGF, SCF, FPH2, FPHH, KL-1, Kitl, SHEP7 | | -KITLG and Acute Myeloid Leukaemia
| 407 |
CEBPA | 19q13.11 | CEBP, C/EBP-alpha | | -CEBPA and Acute Myeloid Leukaemia
| 370 |
KIT | 4q12 | PBT, SCFR, C-Kit, CD117 | | -KIT and Acute Myeloid Leukaemia
| 347 |
WT1 | 11p13 | GUD, AWT1, WAGR, WT33, NPHS4, WIT-2, EWS-WT1 | Overexpression
| -WT1 and Acute Myeloid Leukaemia
| 243 |
NRAS | 1p13.2 | NS6, CMNS, NCMS, ALPS4, N-ras, NRAS1 | | -NRAS and Acute Myeloid Leukaemia
| 231 |
CD33 | 19q13.41 | p67, SIGLEC3, SIGLEC-3 | | -CD33 and Acute Myeloid Leukaemia
| 219 |
MLLT10 | 10p12.31 | AF10 | Translocation
| -t(10;11)(p13;q14) AF10-PICALM translocation in Acute Leukaemia -t(10;11)(p12;q23) AF10-MLL translocation in Acute Leukaemia
| 122 |
IDH1 | 2q33.3 | IDH, IDP, IDCD, IDPC, PICD, HEL-216, HEL-S-26 | | -IDH1 and Acute Myeloid Leukaemia
| 161 |
MYH11 | 16p13.11 | AAT4, FAA4, SMHC, SMMHC | Translocation
| -t(16;16)(p13q22) CBFB-MYH11 Translocation in AML -MYH11 and Acute Myeloid Leukaemia
| 155 |
KMT2A | 11q23.3 | HRX, MLL, MLL1, TRX1, ALL-1, CXXC7, HTRX1, MLL1A, WDSTS | Translocation
| -t(1;11) (q21;q23) in Leukemia -t(6;11)(q27;q23) in Acute Myeloid Leukemia -t(9;11) in Acute Myeloid Leukaemia -t(10;11)(p12;q23) AF10-MLL translocation in Acute Leukaemia -t(10;11) MLL-TET1 rearrangement in acute leukemias -t(1;11)(p32;q23) MLL-EPS15 fusion in Acute Myelogeneous Leukemia -t(11;19)(q23;p13.1) MLL-ELL translocation in acute leukaemia
| 122 |
RUNX1T1 | 8q21.3 | CDR, ETO, MTG8, AML1T1, ZMYND2, CBFA2T1, AML1-MTG8 | Translocation
| - t(8;21)(q22;q22) in Acute Myeloid Leukemia -RUNX1T1 and Acute Myeloid Leukaemia
| 145 |
GATA1 | Xp11.23 | GF1, GF-1, NFE1, XLTT, ERYF1, NF-E1, XLANP, XLTDA, GATA-1 | | -GATA1 and Acute Myeloid Leukaemia
| 141 |
HOXA9 | 7p15.2 | HOX1, ABD-B, HOX1G, HOX1.7 | Translocation
| -t(7;11)(p15;p15) in Acute Myelogenous Leukaemia -HOXA9 and Acute Myeloid Leukaemia
| 105 |
IDH2 | 15q26.1 | IDH, IDP, IDHM, IDPM, ICD-M, D2HGA2, mNADP-IDH | | -IDH2 and Acute Myeloid Leukaemia
| 131 |
ASXL1 | 20q11.21 | MDS, BOPS | | -ASXL1 and Acute Myeloid Leukaemia
| 129 |
RB1 | 13q14.2 | RB, pRb, OSRC, pp110, p105-Rb, PPP1R130 | | -RB1 and Acute Leukaemias
| 125 |
TET2 | 4q24 | MDS, KIAA1546 | | -TET2 and Acute Myeloid Leukaemia
| 120 |
DNMT3A | 2p23 | TBRS, DNMT3A2, M.HsaIIIA | | -DNMT3A and Acute Myeloid Leukaemia
| 110 |
NUP214 | 9q34.13 | CAN, CAIN | Translocation
| -t(6;9)(p23;q34) DEK-NUP214 in Acute Myeloid Leukaemia and Myelodysplastic Syndrome -t(9;9)(q34;q34) SET-NUP214 rearrangements in Acute Lyphoblastic Leukaemia
| 63 |
CD19 | 16p11.2 | B4, CVID3 | | -CD19 and Acute Myeloid Leukaemia
| 104 |
CSF3R | 1p34.3 | SCN7, CD114, GCSFR | | -CSF3R and Acute Myeloid Leukaemia
| 92 |
ETV6 | 12p13.2 | TEL, THC5, TEL/ABL | Translocation
| -t(1;12)(q25;p13) in Leukaemia (AML & ALL) -ETV6 and Acute Myeloid Leukaemia
| 64 |
CD14 | 5q31.3 | | | -CD14 and Acute Myeloid Leukaemia
| 84 |
CD38 | 4p15.32 | ADPRC1, ADPRC 1 | | -CD38 and Acute Myeloid Leukaemia
| 83 |
PICALM | 11q14.2 | LAP, CALM, CLTH | Translocation
| -t(10;11)(p13;q14) AF10-PICALM translocation in Acute Leukaemia
| 76 |
MPL | 1p34.2 | MPLV, TPOR, C-MPL, CD110, THPOR, THCYT2 | | -MPL and Acute Myeloid Leukaemia
| 68 |
TERT | 5p15.33 | TP2, TRT, CMM9, EST2, TCS1, hTRT, DKCA2, DKCB4, hEST2, PFBMFT1 | | -TERT and Acute Myeloid Leukemia
| 66 |
DEK | 6p22.3 | D6S231E | Translocation
| -t(6;9)(p23;q34) DEK-NUP214 in Acute Myeloid Leukaemia and Myelodysplastic Syndrome
| 63 |
GALE | 1p36.11 | SDR1E1 | | -GALE and Acute Myeloid Leukaemia
| 63 |
BAALC | 8q22.3 | | | -BAALC and Acute Myeloid Leukaemia
| 61 |
GATA2 | 3q21.3 | DCML, IMD21, NFE1B, MONOMAC | | -GATA2 and Acute Myeloid Leukaemia
| 60 |
MN1 | 22q12.1 | MGCR, MGCR1, MGCR1-PEN, dJ353E16.2 | | -MN1 and Acute Myeloid Leukaemia
| 50 |
CBL | 11q23.3 | CBL2, NSLL, C-CBL, RNF55, FRA11B | | -CBL and Acute Myeloid Leukaemia
| 48 |
SET | 9q34.11 | 2PP2A, IGAAD, TAF-I, I2PP2A, IPP2A2, PHAPII, TAF-IBETA | Translocation
| -t(9;9)(q34;q34) SET-NUP214 rearrangements in Acute Lyphoblastic Leukaemia
| 46 |
MEIS1 | 2p14 | | | -MEIS1 and Acute Myeloid Leukaemia
| 36 |
MLLT3 | 9p21.3 | AF9, YEATS3 | Translocation
| -t(9;11) in Acute Myeloid Leukaemia -MLLT3 and Acute Myeloid Leukaemia
| 35 |
U2AF1 | 21q22.3 | RN, FP793, U2AF35, U2AFBP, RNU2AF1 | | -U2AF1 and Acute Myeloid Leukaemia
| 33 |
ELL | 19p13.11 | MEN, ELL1, PPP1R68, C19orf17 | Translocation
| -ELL and Acute Myeloid Leukaemia -t(11;19)(q23;p13.1) MLL-ELL translocation in acute leukaemia
| 18 |
NUP98 | 11p15.4 | ADIR2, NUP96, NUP196 | Translocation
| -t(7;11)(p15;p15) in Acute Myelogenous Leukaemia -t(11;20) (p15;q11) NUP98-TOP1 Fusion in AML
| 27 |
PTPN11 | 12q24.13 | CFC, NS1, JMML, SHP2, BPTP3, PTP2C, METCDS, PTP-1D, SH-PTP2, SH-PTP3 | | -PTPN11 and Acute Myeloid Leukaemia
| 29 |
RARS | 5q34 | HLD9, ArgRS, DALRD1 | | -RARS and Acute Myeloid Leukaemia
| 29 |
EGR1 | 5q31.2 | TIS8, AT225, G0S30, NGFI-A, ZNF225, KROX-24, ZIF-268 | | -EGR1 and Acute Myeloid Leukaemia
| 28 |
ABL2 | 1q25.2 | ARG, ABLL | Translocation
| -t(1;12)(q25;p13) in Leukaemia (AML & ALL)
| 25 |
BCOR | Xp11.4 | MAA2, ANOP2, MCOPS2 | | -BCOR and Acute Myeloid Leukaemia
| 24 |
KAT6A | 8p11.21 | MOZ, MRD32, MYST3, MYST-3, ZNF220, RUNXBP2, ZC2HC6A | | -KAT6A and Acute Myeloid Leukaemia
| 23 |
MDS1 | 3q26 | PRDM3, MDS1-EVI1 | | -MDS1 and Acute Myeloid Leukaemia
| 23 |
SRSF2 | 17q25.1 | SC35, PR264, SC-35, SFRS2, SFRS2A, SRp30b | | -SRSF2 and Acute Myeloid Leukaemia
| 20 |
NSD1 | 5q35.3 | STO, KMT3B, SOTOS, ARA267, SOTOS1 | | -NSD1 and Acute Myeloid Leukaemia
| 20 |
CRP | 1q23.2 | PTX1 | | -CRP and Acute Myeloid Leukaemia
| 19 |
ELN | 7q11.23 | WS, WBS, SVAS | | -ELN and Acute Myeloid Leukaemia
| 19 |
RBM15 | 1p13.3 | OTT, OTT1, SPEN | | -RBM15 and Acute Myeloid Leukaemia
| 18 |
HOXA10 | 7p15.2 | PL, HOX1, HOX1H, HOX1.8 | | -HOXA10 and Acute Myeloid Leukaemia
| 17 |
CDX2 | 13q12.2 | CDX3, CDX-3, CDX2/AS | | -CDX2 and Acute Myeloid Leukaemia
| 17 |
PRAME | 22q11.22 | MAPE, OIP4, CT130, OIP-4 | | -PRAME and Acute Myeloid Leukaemia
| 17 |
DOT1L | 19p13.3 | DOT1, KMT4 | | -DOT1L and Acute Myeloid Leukaemia
| 16 |
PRDM16 | 1p36.32 | MEL1, KMT8F, LVNC8, PFM13, CMD1LL | | -PRDM16 and Acute Myeloid Leukaemia
| 16 |
TFAP2A | 6p24.3 | AP-2, BOFS, AP2TF, TFAP2, AP-2alpha | | -TFAP2A and Acute Myeloid Leukaemia
| 16 |
TFAP2C | 20q13.31 | ERF1, TFAP2G, hAP-2g, AP2-GAMMA | | -TFAP2C and Acute Myeloid Leukaemia
| 16 |
STAG2 | Xq25 | SA2, SA-2, SCC3B, NEDXCF, bA517O1.1 | | -STAG2 and Acute Myeloid Leukaemia
| 15 |
BRD4 | 19p13.12 | CAP, MCAP, HUNK1, HUNKI | | -BRD4 and Acute Myeloid Leukaemia
| 15 |
CD36 | 7q21.11 | FAT, GP4, GP3B, GPIV, CHDS7, PASIV, SCARB3, BDPLT10 | | -CD36 and Acute Myeloid Leukaemia
| 14 |
PIM1 | 6p21.2 | PIM | | -PIM1 and Acute Myeloid Leukaemia
| 14 |
SF3B1 | 2q33.1 | MDS, PRP10, Hsh155, PRPF10, SAP155, SF3b155 | | -SF3B1 and Acute Myeloid Leukaemia
| 14 |
FES | 15q26.1 | FPS | | -FES and Acute Myeloid Leukaemia
| 13 |
CBFA2T3 | 16q24.3 | ETO2, MTG16, MTGR2, ZMYND4, RUNX1T3 | | -CBFA2T3 and Acute Myeloid Leukaemia
| 13 |
EPS15 | 1p32.3 | AF1P, AF-1P, MLLT5 | Translocation
| -t(1;11)(p32;q23) MLL-EPS15 fusion in Acute Myelogeneous Leukemia
| 12 |
CEBPB | 20q13.13 | TCF5, IL6DBP, NF-IL6, C/EBP-beta | | -CEBPB and Acute Myeloid Leukaemia
| 12 |
SALL4 | 20q13.2 | DRRS, HSAL4, ZNF797 | | -SALL4 and Acute Myeloid Leukaemia
| 12 |
PHF6 | Xq26.2 | BFLS, BORJ, CENP-31 | | -PHF6 and Acute Myeloid Leukaemia
| 12 |
CHEK1 | 11q24.2 | CHK1 | | -CHEK1 and Acute Myeloid Leukaemia
| 12 |
CSF1R | 5q32 | FMS, CSFR, FIM2, HDLS, C-FMS, CD115, CSF-1R, M-CSF-R | | -CSF1R and Acute Myeloid Leukaemia
| 11 |
ETS2 | 21q22.2 | ETS2IT1 | | -ETS2 and Acute Myeloid Leukaemia
| 11 |
MLF1 | 3q25.32 | | | -MLF1 and Acute Myeloid Leukaemia
| 11 |
JAG1 | 20p12.2 | AGS, AHD, AWS, HJ1, AGS1, DCHE, CD339, JAGL1 | | -JAG1 and Acute Myeloid Leukaemia
| 10 |
MIR10A | 17q21.32 | MIRN10A, mir-10a, miRNA10A, hsa-mir-10a | | -miR-10a and Acute Myeloid Leukaemia
| 10 |
HOXA5 | 7p15.2 | HOX1, HOX1C, HOX1.3 | | -HOXA5 and Acute Myeloid Leukaemia
| 10 |
PBX3 | 9q33.3 | | | -PBX3 and Acute Myeloid Leukaemia
| 10 |
HOXB4 | 17q21.32 | HOX2, HOX2F, HOX-2.6 | | -HOXB4 and Acute Myeloid Leukaemia
| 9 |
ITGAM | 16p11.2 | CR3A, MO1A, CD11B, MAC-1, MAC1A, SLEB6 | | -ITGAM and Acute Myeloid Leukaemia
| 9 |
HOXD13 | 2q31.1 | BDE, SPD, BDSD, HOX4I | | -HOXD13 and Acute Myeloid Leukaemia
| 9 |
GALM | 2p22.1 | GLAT, IBD1, BLOCK25, HEL-S-63p | | -GALM and Acute Myeloid Leukaemia
| 9 |
IL2RG | Xq13.1 | P64, CIDX, IMD4, CD132, SCIDX, IL-2RG, SCIDX1 | | -IL2RG and Acute Myeloid Leukaemia
| 9 |
WARS | 14q32.2 | IFI53, IFP53, GAMMA-2 | | -WARS and Acute Myeloid Leukaemia
| 9 |
PAPPA | 9q33.1 | PAPA, DIPLA1, PAPP-A, PAPPA1, ASBABP2, IGFBP-4ase | | -PAPPA and Acute Myeloid Leukaemia
| 8 |
ABCC1 | 16p13.11 | MRP, ABCC, GS-X, MRP1, ABC29 | | -ABCC1 (MRP1) Deletion in AML with Inversion of Chromosome 16
| 8 |
IL21R | 16p12.1 | NILR, CD360 | | -IL21R and Acute Myeloid Leukaemia
| 8 |
SEPT9 | 17q25.3 | MSF, MSF1, NAPB, SINT1, PNUTL4, SeptD1, AF17q25 | | -SEPT9 and Acute Myeloid Leukaemia
| 7 |
SEPTIN6 | Xq24 | SEP2, SEPT2, SEPT6 | | -SEPT6 and Acute Myeloid Leukaemia
| 7 |
DDX10 | 11q22.3 | HRH-J8 | | -DDX10 and Acute Myeloid Leukaemia
| 7 |
ZRSR2 | Xp22.2 | URP, ZC3H22, U2AF1L2, U2AF1RS2, U2AF1-RS2 | | -ZRSR2 and Acute Myeloid Leukaemia
| 7 |
PIM2 | Xp11.23 | | | -PIM2 and Acute Myeloid Leukaemia
| 7 |
WT1-AS | 11p13 | WIT1, WIT-1, WT1AS, WT1-AS1 | | -WT1-AS and Acute Myeloid Leukaemia
| 7 |
MLLT6 | 17q12 | AF17 | | -MLLT6 and Acute Myeloid Leukaemia
| 7 |
RPN1 | 3q21.3 | OST1, RBPH1 | | -RPN1 and Acute Myeloid Leukaemia
| 6 |
CDC25B | 20p13 | | | -CDC25B and Acute Myeloid Leukaemia
| 6 |
ARHGAP26 | 5q31.3 | GRAF, GRAF1, OPHN1L, OPHN1L1 | | -ARHGAP26 and Acute Myeloid Leukaemia
| 6 |
HOXB3 | 17q21.32 | HOX2, HOX2G, Hox-2.7 | | -HOXB3 and Acute Myeloid Leukaemia
| 6 |
MLLT1 | 19p13.3 | ENL, LTG19, YEATS1 | | -MLLT1 and Acute Myeloid Leukaemia
| 6 |
HCK | 20q11.21 | JTK9, p59Hck, p61Hck | | -HCK and Acute Myeloid Leukaemia
| 6 |
IRF8 | 16q24.1 | ICSBP, IRF-8, ICSBP1, IMD32A, IMD32B, H-ICSBP | | -IRF8 and Acute Myeloid Leukaemia
| 6 |
CEBPE | 14q11.2 | CRP1, C/EBP-epsilon | | -CEBPE and Acute Myeloid Leukaemia
| 6 |
MNX1 | 7q36.3 | HB9, HLXB9, SCRA1, HOXHB9 | | -MNX1 and Acute Myeloid Leukaemia
| 6 |
PTPRC | 1q31.3-q32.1 | LCA, LY5, B220, CD45, L-CA, T200, CD45R, GP180 | | -PTPRC and Acute Myeloid Leukaemia
| 6 |
HOXA7 | 7p15.2 | ANTP, HOX1, HOX1A, HOX1.1 | | -HOXA7 and Acute Myeloid Leukaemia
| 6 |
HAVCR2 | 5q33.3 | TIM3, CD366, KIM-3, TIMD3, Tim-3, TIMD-3, HAVcr-2 | | -HAVCR2 and Acute Myeloid Leukaemia
| 6 |
LARS | 5q32 | LRS, LEUS, LFIS, ILFS1, LARS1, LEURS, PIG44, RNTLS, HSPC192, hr025Cl | | -LARS and Acute Myeloid Leukaemia
| 6 |
MX1 | 21q22.3 | MX, MxA, IFI78, IFI-78K | | -MX1 and Acute Myeloid Leukaemia
| 6 |
TXNIP | 1q21.1 | THIF, VDUP1, ARRDC6, HHCPA78, EST01027 | | -TXNIP and Acute Myeloid Leukaemia
| 5 |
SUV39H1 | Xp11.23 | MG44, KMT1A, SUV39H, H3-K9-HMTase 1 | | -SUV39H1 and Acute Myeloid Leukaemia
| 5 |
MSI2 | 17q22 | MSI2H | | -MSI2 and Acute Myeloid Leukaemia
| 5 |
NCOA2 | 8q13.3 | SRC2, TIF2, GRIP1, KAT13C, NCoA-2, bHLHe75 | | -NCOA2 and Acute Myeloid Leukaemia
| 5 |
BOLL | 2q33 | BOULE | | -BOLL and Acute Myeloid Leukaemia
| 5 |
SFRP5 | 10q24.2 | SARP3 | | -SFRP5 and Acute Myeloid Leukaemia
| 5 |
MYH9 | 22q12.3 | MHA, FTNS, EPSTS, BDPLT6, DFNA17, MATINS, NMMHCA, NMHC-II-A, NMMHC-IIA | | -MYH9 and Acute Myeloid Leukaemia
| 5 |
SFRP4 | 7p14.1 | PYL, FRP-4, FRPHE, sFRP-4 | | -SFRP4 and Acute Myeloid Leukaemia
| 5 |
RAD21 | 8q24.11 | HR21, MCD1, NXP1, SCC1, CDLS4, hHR21, HRAD21 | | -RAD21 and Acute Myeloid Leukaemia
| 5 |
HOXA4 | 7p15.2 | HOX1, HOX1D | | -HOXA4 and Acute Myeloid Leukaemia
| 5 |
SOCS2 | 12q22 | CIS2, SSI2, Cish2, SSI-2, SOCS-2, STATI2 | | -SOCS2 and Acute Myeloid Leukaemia
| 5 |
BCL11B | 14q32.2 | ATL1, RIT1, CTIP2, IMD49, CTIP-2, ZNF856B, ATL1-beta, ATL1-alpha, ATL1-delta, ATL1-gamma, hRIT1-alpha | | -BCL11B and Acute Myeloid Leukaemia
| 5 |
GAB2 | 11q14.1 | | | -GAB2 and Acute Myeloid Leukaemia
| 5 |
HOXA13 | 7p15.2 | HOX1, HOX1J | | -HOXA13 and Acute Myeloid Leukaemia
| 4 |
GAS6 | 13q34 | AXSF, AXLLG | | -GAS6 and Acute Myeloid Leukaemia
| 4 |
TOP1 | 20q12 | TOPI | Translocation
| -t(11;20) (p15;q11) NUP98-TOP1 Fusion in AML
| 4 |
PLK2 | 5q11.2 | SNK, hSNK, hPlk2 | | -PLK2 and Acute Myeloid Leukaemia
| 4 |
GMPS | 3q25.31 | | | -GMPS and Acute Myeloid Leukaemia
| 4 |
IL2RA | 10p15.1 | p55, CD25, IL2R, IMD41, TCGFR, IDDM10 | | -IL2RA and Acute Myeloid Leukaemia
| 4 |
CBFB | 16q22.1 | PEBP2B | Translocation
| -t(16;16)(p13q22) CBFB-MYH11 Translocation in AML
| 4 |
CEBPD | 8q11.21 | CELF, CRP3, C/EBP-delta, NF-IL6-beta | | -CEBPD and Acute Myeloid Leukaemia
| 4 |
KLF5 | 13q22.1 | CKLF, IKLF, BTEB2 | | -KLF5 and Acute Myeloid Leukaemia
| 4 |
ULBP2 | 6q25 | N2DL2, RAET1H, NKG2DL2, ALCAN-alpha | | -ULBP2 and Acute Myeloid Leukaemia
| 4 |
CCDC26 | 8q24.21 | RAM | | -CCDC26 and Acute Myeloid Leukaemia
| 4 |
IL23R | 1p31.3 | | | -IL23R and Acute Myeloid Leukaemia
| 4 |
HHEX | 10q23.33 | HEX, PRH, HMPH, PRHX, HOX11L-PEN | | -HHEX and Acute Myeloid Leukaemia
| 4 |
TET1 | 10q21.3 | LCX, CXXC6, bA119F7.1 | Translocation
| -t(10;11) MLL-TET1 rearrangement in acute leukemias
| 4 |
SPRED1 | 15q14 | NFLS, hSpred1, spred-1, PPP1R147 | | -SPRED1 and Acute Myeloid Leukaemia
| 3 |
SEPTIN5 | 22q11.21 | H5, SEPT5, CDCREL, PNUTL1, CDCREL1, CDCREL-1, HCDCREL-1 | | -SEPT5 and Acute Myeloid Leukaemia
| 3 |
GNL3 | 3p21.1 | NS, E2IG3, NNP47, C77032 | | -GNL3 and Acute Myeloid Leukaemia
| 3 |
GLIPR1 | 12q21.2 | GLIPR, RTVP1, CRISP7 | | -GLIPR1 and Acute Myeloid Leukaemia
| 3 |
GUSB | 7q11.21 | BG, MPS7 | | -GUSB and Acute Myeloid Leukaemia
| 3 |
HOXC11 | 12q13.13 | HOX3H | | -HOXC11 and Acute Myeloid Leukaemia
| 3 |
SMAD5 | 5q31.1 | DWFC, JV5-1, MADH5 | | -SMAD5 and Acute Myeloid Leukaemia
| 3 |
CD200 | 3q13.2 | MRC, MOX1, MOX2, OX-2 | | -CD200 and Acute Myeloid Leukaemia
| 3 |
ELF4 | Xq26.1 | MEF, ELFR | | -ELF4 and Acute Myeloid Leukaemia
| 3 |
HOXC13 | 12q13.13 | HOX3, ECTD9, HOX3G | | -HOXC13 and Acute Myeloid Leukaemia
| 3 |
HLA-DQB1 | 6p21.32 | IDDM1, CELIAC1, HLA-DQB | | -HLA-DQB1 and Acute Myeloid Leukaemia
| 3 |
FUT4 | 11q21 | LeX, CD15, ELFT, FCT3A, FUTIV, SSEA-1, FUC-TIV | | -FUT4 and Acute Myeloid Leukaemia
| 3 |
TNFRSF9 | 1p36.23 | ILA, 4-1BB, CD137, CDw137 | | -TNFRSF9 and Acute Myeloid Leukaemia
| 3 |
KDM4C | 9p24.1 | GASC1, JHDM3C, JMJD2C, TDRD14C | | -KDM4C and Acute Myeloid Leukaemia
| 3 |
HOXA11 | 7p15.2 | HOX1, HOX1I, RUSAT1 | | -HOXA11 and Acute Myeloid Leukaemia
| 3 |
SBDS | 7q11.21 | SDS, SWDS, CGI-97 | | -SBDS and Acute Myeloid Leukaemia
| 3 |
FLNA | Xq28 | FLN, FMD, MNS, OPD, ABPX, CSBS, CVD1, FGS2, FLN1, NHBP, OPD1, OPD2, XLVD, XMVD, FLN-A, ABP-280 | | -FLNA and Acute Myeloid Leukaemia
| 3 |
DLX4 | 17q21.33 | BP1, DLX7, DLX8, DLX9, OFC15 | | -DLX4 and Acute Myeloid Leukaemia
| 3 |
HLA-DRA | 6p21.32 | HLA-DRA1 | | -HLA-DRA and Acute Myeloid Leukaemia
| 2 |
MERTK | 2q14.1 | MER, RP38, c-Eyk, c-mer, Tyro12 | | -MERTK and Acute Myeloid Leukaemia
| 2 |
MBL2 | 10q21.1 | MBL, MBP, MBP1, MBPD, MBL2D, MBP-C, COLEC1, HSMBPC | | -MBL2 and Acute Myeloid Leukaemia
| 2 |
CHAT | 10q11.23 | CMS6, CMS1A, CMS1A2, CHOACTASE | | -CHAT and Acute Myeloid Leukaemia
| 2 |
PRTN3 | 19p13.3 | MBN, MBT, NP4, P29, PR3, ACPA, AGP7, NP-4, PR-3, CANCA, C-ANCA | | -PRTN3 and Acute Myeloid Leukaemia
| 2 |
PAWR | 12q21 | PAR4, Par-4 | | -PAWR and Acute Myeloid Leukaemia
| 2 |
TYRO3 | 15q15.1 | BYK, Dtk, RSE, Rek, Sky, Tif, Etk-2 | | -TYRO3 and Acute Myeloid Leukaemia
| 2 |
ESPL1 | 12q13.13 | ESP1, SEPA | | -ESPL1 and Acute Myeloid Leukaemia
| 2 |
PSIP1 | 9p22.3 | p52, p75, PAIP, DFS70, LEDGF, PSIP2 | | -PSIP1 and Acute Myeloid Leukaemia
| 2 |
CXCL11 | 4q21.1 | IP9, H174, IP-9, b-R1, I-TAC, SCYB11, SCYB9B | | -CXCL11 and Acute Myeloid Leukaemia
| 2 |
IGK | 2p12 | IGK@ | | -IGK and Acute Myeloid Leukaemia
| 2 |
BLNK | 10q24.1 | bca, AGM4, BASH, LY57, SLP65, BLNK-S, SLP-65 | | -BLNK and Acute Myeloid Leukaemia
| 2 |
TLE1 | 9q21.32 | ESG, ESG1, GRG1 | | -TLE1 and Acute Myeloid Leukaemia
| 2 |
CTDSPL | 3p22.2 | PSR1, SCP3, HYA22, RBSP3, C3orf8 | | -CTDSPL and Acute Myeloid Leukaemia
| 2 |
DLEU2 | 13q14.2 | 1B4, DLB2, LEU2, BCMSUN, RFP2OS, MIR15AHG, TRIM13OS, LINC00022, NCRNA00022 | | -DLEU2 and Acute Myeloid Leukaemia
| 2 |
CD48 | 1q23.3 | BCM1, BLAST, hCD48, mCD48, BLAST1, SLAMF2, MEM-102 | | -CD48 and Acute Myeloid Leukaemia
| 2 |
MUC3A | 7q22.1 | MUC3, MUC-3A | | -MUC3A and Acute Myeloid Leukaemia
| 2 |
PDCD1LG2 | 9p24.1 | B7DC, Btdc, PDL2, CD273, PD-L2, PDCD1L2, bA574F11.2 | | -PDCD1LG2 and Acute Myeloid Leukaemia
| 2 |
LAMP1 | 13q34 | LAMPA, CD107a, LGP120 | | -LAMP1 and Acute Myeloid Leukaemia
| 2 |
HMMR | 5q34 | CD168, IHABP, RHAMM | | -HMMR and Acute Myeloid Leukaemia
| 2 |
HLA-E | 6p21.3 | MHC, QA1, EA1.2, EA2.1, HLA-6.2 | | -HLA-E and Acute Myeloid Leukaemia
| 2 |
TPMT | 6p22.3 | TPMTD | | -TPMT and Acute Myeloid Leukaemia
| 2 |
IRF2 | 4q35.1 | IRF-2 | | -IRF2 and Acute Myeloid Leukaemia
| 2 |
CNTRL | 9q33.2 | FAN, CEP1, CEP110, bA165P4.1 | | -CNTRL and Acute Myeloid Leukaemia
| 2 |
POLI | 18q21.2 | RAD30B, RAD3OB | | -POLI and Acute Myeloid Leukaemia
| 2 |
HLA-DQA1 | 6p21.32 | DQ-A1, CELIAC1, HLA-DQA | | -HLA-DQA1 and Acute Myeloid Leukaemia
| 1 |
SFPQ | 1p34.3 | PSF, POMP100, PPP1R140 | | -SFPQ and Acute Myeloid Leukaemia
| 1 |
DNM2 | 19p13.2 | DYN2, CMT2M, DYNII, LCCS5, CMTDI1, CMTDIB, DI-CMTB | | -DNM2 and Acute Myeloid Leukaemia
| 1 |
HSP90AB1 | 6p21.1 | HSP84, HSPC2, HSPCB, D6S182, HSP90B | | -HSP90AB1 and Acute Myeloid Leukaemia
| 1 |
SH3GL1 | 19p13.3 | EEN, CNSA1, SH3P8, SH3D2B | | -SH3GL1 and Acute Myeloid Leukaemia
| 1 |
ABI2 | 2q33 | ABI-2, ABI2B, AIP-1, AblBP3, argBP1, SSH3BP2, argBPIA, argBPIB | | -ABI2 and Acute Myeloid Leukaemia
| 1 |
LRRC3B | 3p24.1 | LRP15 | | -LRRC3B and Acute Myeloid Leukaemia
| 1 |
PDCD7 | 15q22.31 | ES18, HES18 | | -PDCD7 and Acute Myeloid Leukaemia
| 1 |
ERRFI1 | 1p36.23 | MIG6, RALT, MIG-6, GENE-33 | | -ERRFI1 and Acute Myeloid Leukaemia
| 1 |
HSP90AA1 | 14q32.31 | EL52, HSPN, LAP2, HSP86, HSPC1, HSPCA, Hsp89, Hsp90, LAP-2, HSP89A, HSP90A, HSP90N, Hsp103, HSPCAL1, HSPCAL4, HEL-S-65p | | -HSP90AA1 and Acute Myeloid Leukaemia
| 1 |
BRD3 | 9q34.2 | ORFX, RING3L | | -BRD3 and Acute Myeloid Leukaemia
| 1 |
SERPINB2 | 18q21.33-q22.1 | PAI, PAI2, PAI-2, PLANH2, HsT1201 | | -SERPINB2 and Acute Myeloid Leukaemia
| 1 |
PNN | 14q21.1 | DRS, DRSP, SDK3, memA | | -PNN and Acute Myeloid Leukaemia
| 1 |
RMI1 | 9q21.32 | BLAP75, FAAP75, C9orf76 | | -RMI1 and Acute Myeloid Leukaemia
| 1 |
ECT2L | 6q24.1 | LFDH, FBXO49, C6orf91, ARHGEF32, dJ509I19.2, dJ509I19.3, dJ509I19.5 | | -ECT2L and Acute Myeloid Leukaemia
| 1 |
ZNF384 | 12p13.31 | NP, CIZ, NMP4, CAGH1, ERDA2, TNRC1, CAGH1A | | -ZNF384 and Acute Myeloid Leukaemia
| 1 |
DOK2 | 8p21.3 | p56DOK, p56dok-2 | | -DOK2 and Acute Myeloid Leukaemia
| 1 |
CBLB | 3q13.11 | Cbl-b, RNF56, Nbla00127 | | -CBLB and Acute Myeloid Leukaemia
| 1 |
NACA | 12q13.3 | HSD48, NACA1, skNAC, NAC-alpha | | -NACA and Acute Myeloid Leukaemia
| 1 |
ACSL6 | 5q31.1 | ACS2, FACL6, LACS2, LACS5, LACS 6 | | -ACSL6 and Acute Myeloid Leukaemia
| 1 |
IL1RL1 | 2q12 | T1, ST2, DER4, ST2L, ST2V, FIT-1, IL33R | | -IL1RL1 and Acute Myeloid Leukaemia
| 1 |
ST2 | 11p14.3-p12 | | | -ST2 and Acute Myeloid Leukaemia
| 1 |
FGFR1OP | 6q27 | FOP | | -FGFR1OP and Acute Myeloid Leukaemia
| 1 |
TFAP2B | 6p12.3 | PDA2, AP-2B, AP2-B | | -TFAP2B and Acute Myeloid Leukaemia
| |
DTX2P1-UPK3B | 7q11.23 | PMS2L11 | | -DTX2P1-UPK3B and Acute Myeloid Leukaemia
| |
FUS | 16p11.2 | TLS, ALS6, ETM4, FUS1, POMP75, HNRNPP2 | Translocation
| -t(16;21)(p11;q22) in Leukemia (ANLL) -t(16;21)(p11;q22) FUS-ERG in Acute Myelogenous Leukemia
| |
AFDN | 6q27 | AF6, MLLT4, MLL-AF6, l-afadin | Translocation
| -t(6;11)(q27;q23) in Acute Myeloid Leukemia
| |
MLLT11 | 1q21.3 | AF1Q | Translocation
| -t(1;11) (q21;q23) in Leukemia -Elevated AF1q/MLLT11 protein expression is an adverse prognostic marker in AML
| |
MECOM | 3q26.2 | EVI1, MDS1, KMT8E, PRDM3, RUSAT2, MDS1-EVI1, AML1-EVI-1 | Translocation
| -t(3;21)(q26;q22) in Secondary Leukaemia / MDS
| |
RARA | 17q21.2 | RAR, NR1B1 | Translocation
| -t(11;17)(q32;q21) RARA-PLZF in Acute Promyelocytic Leukemia
| |
ZBTB16 | 11q23.2 | PLZF, ZNF145 | Translocation
| -t(11;17)(q32;q21) RARA-PLZF in Acute Promyelocytic Leukemia
| |
ERG | 21q22.2 | p55, erg-3 | Translocation
| -t(16;21)(p11;q22) in Leukemia (ANLL) -t(16;21)(p11;q22) FUS-ERG in Acute Myelogenous Leukemia
| |
RUNX1 | 21q22.12 | AML1, CBFA2, EVI-1, AMLCR1, PEBP2aB, CBF2alpha, AML1-EVI-1, PEBP2alpha | Translocation
| - t(8;21)(q22;q22) in Acute Myeloid Leukemia -t(3;21)(q26;q22) in Secondary Leukaemia / MDS
| |